vatalanib has been researched along with irinotecan in 7 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | vatalanib (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Barber, SE; Bekele, BN; Jasser, SA; Kim, S; Mandal, M; Myers, JN; Yazici, YD | 1 |
| Borner, MM | 1 |
| Eng, C; Shalan, N | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Fu, LW; Lin, G; Poon, DC; To, KK; Wang, F; Wei, Y | 1 |
3 review(s) available for vatalanib and irinotecan
| Article | Year |
|---|---|
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
4 other study(ies) available for vatalanib and irinotecan
| Article | Year |
|---|---|
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Thyroid Neoplasms | 2006 |
Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins | 2015 |